Clinical Trial: Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Randomized phase III trial to compare surgery with or without chemotherapy in treating patients who have stage IB cervical cancer.

Condition Treatment or Intervention Phase
stage IB cervical cancer
 Drug: cisplatin
 Drug: vincristine
Phase III

MedlinePlus related topics:  Cervical Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase III Randomized Study of Radical Hysterectomy and Pelvic and Para-Aortic Lymphadenectomy With or Without Neoadjuvant Vincristine and Cisplatin in Patients with Bulky Stage IB Carcinoma of the Cervix

Further Study Details: 

Study start: December 1996

OBJECTIVES: I. Compare disease free survival, overall survival, and local control in patients with bulky stage IB carcinoma of the cervix treated with radical hysterectomy and pelvic and para-aortic lymphadenectomy with or without neoadjuvant vincristine and cisplatin. II. Compare adverse effects of radical hysterectomy and pelvic and para-aortic lymphadenectomy with or without neoadjuvant vincristine and cisplatin in these patients.

PROTOCOL OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. Arm I: Surgery. All patients undergo intra-abdominal and retroperitoneal exploratory laparotomy. Patients without metastases also undergo radical hysterectomy with pelvic and para-aortic lymphadenectomy. Beginning 2-4 weeks after surgery, patients with 1 or more positive lymph nodes or positive surgical margins on the radical hysterectomy specimen receive adjunctive radiotherapy 5 days each week for 4-6 weeks. Patients with histologically confirmed metastases do not undergo radical hysterectomy with pelvic and para-aortic lymphadenectomy, but receive radiotherapy 5 days each week for 6-8 weeks beginning 2-4 weeks after the laparotomy. Patients who undergo radiotherapy also receive cisplatin IV over 1 hour on days when radiotherapy is administered for up to 6 doses of cisplatin. Arm II: Patients receive vincristine IV bolus immediately followed by cisplatin IV over 1 hour on days 1, 11, and 21. Courses repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Beginning approximately 4 weeks after the last doses of neoadjuvant vincristine and cisplatin, patients receive surgery, radiotherapy, and cisplatin as in Arm I. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 170-340 patients will be accrued for this study over approximately 4.5 years.




--Disease Characteristics--

  • Previously untreated, histologically proven invasive carcinoma of the cervix
  • Eligible histologies: Squamous; Adenocarcinoma; Adenosquamous
  • Eligible stages: Bulky stage IB, i.e.: Exophytic lesions 4 cm or greater in diameter OR Cervix expanded to 4 cm or greater and presumed clinically to result from cancer; No extension beyond cervix clinically and by IVP or CT with contrast

--Prior/Concurrent Therapy--

--Patient Characteristics--

Location Information

      University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham,  Alabama,  35294-3300,  United States

      Chao Family Comprehensive Cancer Center, Orange,  California,  92868,  United States

      Community Hospital of Los Gatos, Los Gatos,  California,  95032,  United States

      Jonsson Comprehensive Cancer Center, UCLA, Los Angeles,  California,  90095-1781,  United States

      Southern California Permanante Medical Group, Bellflower,  California,  90706,  United States

      University of Colorado Cancer Center, Denver,  Colorado,  80010,  United States

District of Columbia
      Walter Reed Army Medical Center, Washington,  District of Columbia,  20307-5000,  United States

      H. Lee Moffitt Cancer Center and Research Institute, Tampa,  Florida,  33612-9497,  United States

      Rush-Presbyterian-St. Luke's Medical Center, Chicago,  Illinois,  60612,  United States

      University of Chicago Cancer Research Center, Chicago,  Illinois,  60637-1470,  United States

      Indiana University Cancer Center, Indianapolis,  Indiana,  46202-5289,  United States

      Holden Comprehensive Cancer Center at The University of Iowa, Iowa City,  Iowa,  52242-1009,  United States

      Albert B. Chandler Medical Center, University of Kentucky, Lexington,  Kentucky,  40536-0084,  United States

      Tufts University School of Medicine, Boston,  Massachusetts,  02111,  United States

      University of Massachusetts Memorial Medical Center, Worcester,  Massachusetts,  01655,  United States

      Barbara Ann Karmanos Cancer Institute, Detroit,  Michigan,  48201-1379,  United States

      University of Minnesota Cancer Center, Minneapolis,  Minnesota,  55455,  United States

      University of Mississippi Medical Center, Jackson,  Mississippi,  39216-4505,  United States

      Washington University School of Medicine, Saint Louis,  Missouri,  63110,  United States

New Jersey
      Cooper Hospital/University Medical Center, Camden,  New Jersey,  08103,  United States

      Morristown Memorial Hospital, Morristown,  New Jersey,  07962-1956,  United States

New York
      Cancer Center of Albany Medical Center, Albany,  New York,  12208,  United States

      State University of New York Health Science Center at Brooklyn, Brooklyn,  New York,  11203,  United States

      State University of New York Health Sciences Center - Stony Brook, Stony Brook,  New York,  11790-7775,  United States

North Carolina
      Comprehensive Cancer Center at Wake Forest University, Winston Salem,  North Carolina,  27157-1082,  United States

      Duke Comprehensive Cancer Center, Durham,  North Carolina,  27710,  United States

      Lineberger Comprehensive Cancer Center, UNC, Chapel Hill,  North Carolina,  27599-7295,  United States

      Arthur G. James Cancer Hospital - Ohio State University, Columbus,  Ohio,  43210-1240,  United States

      Barrett Cancer Center, The University Hospital, Cincinnati,  Ohio,  45219,  United States

      Ireland Cancer Center, Cleveland,  Ohio,  44106-5065,  United States

      University of Oklahoma College of Medicine, Oklahoma City,  Oklahoma,  73190,  United States

      Abington Memorial Hospital, Abington,  Pennsylvania,  19001,  United States

      Fox Chase Cancer Center, Philadelphia,  Pennsylvania,  19111,  United States

      Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia,  Pennsylvania,  19107-5541,  United States

      Milton S. Hershey Medical Center, Hershey,  Pennsylvania,  17033,  United States

      University of Pennsylvania Cancer Center, Philadelphia,  Pennsylvania,  19104-4283,  United States

      Brookview Research, Inc., Nashville,  Tennessee,  37203,  United States

      Fletcher Allen Health Care, Burlington,  Vermont,  05401,  United States

      Cancer Center at the University of Virginia, Charlottesville,  Virginia,  22908,  United States

      Fred Hutchinson Cancer Research Center, Seattle,  Washington,  98109-1024,  United States

      Tacoma General Hospital, Tacoma,  Washington,  98405,  United States

Study chairs or principal investigators

Gary Lee Eddy,  Study Chair,  Gynecologic Oncology Group   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000078470; GOG-141
Record last reviewed:  March 2004
Last Updated:  October 13, 2004
Record first received:  November 1, 1999 Identifier:  NCT00002536
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005